In the past decade, several tumor-associated antigens have been reported to induce immune responses in acute myeloid leukemia (AML) patients. These antigens include human telomerase reverse transcriptase, proteinase 3, Wilms' tumor 1 protein, the preferentially expressed antigen in melanoma protein, survivin and the receptor for hyaluronic acid-mediated motility (RHAMM). [1] [2] [3] The M-phase phosphoprotein 11 (MPP11) gene, a member of the MPP family, encodes a 66 kDa protein and is located on the chromosome 7q22-q31.1. [2] [3] [4] It has been documented that MPP11 is capable of forming a heterodimeric complex that associates with ribosomes, acting as a molecular chaperone for nascent polypeptide chains as they exit the ribosome. 5, 6 By using serological screening of an expression library, Greiner et al. described MPP11 as a cancer testis antigen, which is highly upregulated in malignant myeloblasts in patients with AML and chronic myeloid leukemia, but is absent in normal differentiated tissues except for testis. In a small sample size, the authors were capable of showing significant titers of anti-MPP11 antibodies in some AML and chronic myeloid leukemia patients. 2, 3 In the current study, we identified T-cell epitopes capable of inducing specific cytotoxic T cell line responses in samples of human leukocyte antigen (HLA)-A n 0201-positive AML patients. As documented in western blot analysis, high expression levels of MPP11 were found in all AML samples tested, whereas MPP11 protein expression in normal, different hematopoietic subpopulations was absent (Figures 1a  and b) . To identify T cell-binding epitopes deduced from MPP11 protein, eight peptides were synthesized that were predicted by the computer programs PAProC (www.uni-tuebingen.de/uni/kxi/) and SYFPEITHI (www.syfpeithi.de) to bind to the HLA-A n 0201 molecule.
MPP11 peptides were then tested for their potential to elicit specific ex vivo T-cell responses in healthy volunteers and in patients with AML. To extend the sensitivity of the ELISPOT assay, peripheral blood mononuclear cells were stimulated with MPP11 peptides once in vitro before analysis. As depicted in Figures 1c and d , for 'peptide 2' in 16 of 32 (50%) samples of untreated AML patients (peripheral blood mononuclear cells) significant frequencies of MPP11-specific T-cell responses were detected, whereas no spontaneous T-cell responses against this peptide epitope occurred in peripheral blood mononuclear cells of 15 HLA-A2 n 0201-positive healthy individuals. For peptide 1 and peptides 3-8 spontaneous T-cell responses could be measured as well. We next generated MPP11-specific cytotoxic T cell lines in the presence of the 'peptide 2' (also named as MPP11-ASK-A2, amino acid sequence QLLIKAVNL, MPP11 [421] [422] [423] [424] [425] [426] [427] [428] [429] ). Cytotoxic T cell lines specific for MPP11 421-429 recognized and efficiently killed MPP11 þ primary malignant cells from patients with AML (Figures 1e and f) without attacking HLA-A2-negative tumor cells. Antibody-blocking experiments revealed a major histocompatibility complex class I-restricted killing process induced by peptide-specific CD8 þ T lymphocytes (Figure 1g ). Taken together, for the first time we identified major histocompatibility complex class I (HLA-A n 0201) specific T-cell epitopes deduced from the tumor-associated antigen MPP11. These findings emphasize that MPP11 is a promising target for T cell-based immunotherapeutic strategies in patients with AML.
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This work was supported by part of the Wilhelm Sander Stiftung. Cr release assay with various effector to target (E:T) ratios. CTLs were generated from two AML patients being in complete remission after transplantation of HLA-identical allogeneic stem cells derived from matched related donors. Graft-versus-host disease prophylaxis was stopped for more than 6 months before CTL induction was started (e, f). Antibody-blocking experiments document the specificity of MPP11 peptide-specific CTLs. Malignant myeloblasts from patient AML-01 were used as targets (g). moAb, monoclonal antibody. The development of increasingly immunocompromised mice has allowed for improved engraftment of human tissue in xenograft hosts. NOD/SCID IL2Rgamma-c null mice (NSG) represent the latest iterative attempt to limit both the innate and acquired immune function in mice, thus preventing immune surveillance during xenografting. NSG mice have severe T-and B-cell impairment, as well as a complete absence of natural killer-cells. 1,2 Carroll and colleagues 3 have recently reported in Leukemia the engraftment of human acute myeloid leukemia cells in the bone marrow of NSG mice, suggesting that NSG mice may be more permissive to human malignant myeloid cell engraftment than the previous xenograft hosts. To date, there has been only limited success in establishing a robust xenograft model of low-risk myelodysplastic syndromes (MDS) despite the use of a variety of immune deficient and transgenic mice. In an attempt to improve on these models, we tested whether the increased deficiency in natural killer cell function in NSG mice might improve the myeloid cell engraftment of MDS samples with low myeloblast counts and provide a useful pre-clinical model of low-risk MDS. [4] [5] [6] [7] In all, 34 NSG mice were injected with unfractionated, T-cell depleted, or CD34 þ purified bone marrow cells from consented normal donors (three samples into 2-3 mice each), patients with acute myeloid leukemia (four samples into 1-2 mice each), or patients with MDS and bone marrow myeloblast counts ranging from 0-13% (five samples into 3-5 mice each) 24 h after recipient mice received 250 cGy total body irradiation ( Figure 1a ). All samples were previously cryopreserved, and engraftment was defined as 40.1% human CD45 þ cells. Trilineage hematopoietic engraftment of human cells was analyzed in the peripheral blood, bone marrow and spleens of NSG mice 12 weeks post-injection, or when an animal was moribund (Figures 1a-c and data not shown) . Bone marrow engraftment was significantly higher in NSG mice following retro-orbital injection of unfractionated normal bone marrow compared with MDS bone marrow cells (average 22.3 vs 1.6%, respectively, P ¼ 0.03). All mice receiving normal or MDS cells had o0.1% human CD33
þ cells in their bone marrow (Figure 1b) , and only MDS sample 4 had any splenic CD33 þ engraftment in two mice (0.38-0.78%). (Figure 1c ). Several engrafted mice became moribund with weight loss, ruffled fur and failure to thrive. Pathological examination of the lung and liver from a MDSinjected moribund mouse, revealed human CD3 þ cell infiltration, consistent with graft versus host disease (Figures 1d and e) .
We attempted to improve engraftment of human myeloid cells by injecting whole bone marrow cells intra-tibial (to abrogate potential trafficking/homing defects), by T-cell depleting-bone marrow samples (to limit the number of T cells that may contribute to graft versus host disease) and by injecting CD34 þ purified cells. Four out of five animals that received an intra-tibial injection of bone marrow cells died unexpectedly 40-56 days after injection (MDS samples 5, 6). The remaining intra-tibial injected mouse from MDS sample 6 had 0.12% peripheral blood human engraftment at 6 weeks (100% T-cells), suggesting that graft-versus-host disease may have contributed to the death of the other intra-tibial injected mice. Next, we retro-orbital injected T-cell depleted-bone marrow cells (42 log reduction in T cells) from MDS samples 5 and 6. Both samples had 0.2% human cell engraftment in the spleen, but no engraftment in the peripheral blood or bone marrow. Surprisingly, engrafted human cells were predominantly CD3 þ (70-80%), suggesting that T-cell expansion in NSG mice is robust even when less than 900 T cells were injected. Finally, we injected CD34 þ purified cells (autoMACS, Miltenyi, Auburn, CA, USA) from normal or MDS bone marrow cells. One mouse receiving normal CD34 þ bone marrow cells had 0.17% bone marrow engraftment, which consisted predominantly of B cells (95%). CD34 þ purified cells from three MDS samples (5, 6, 8) were injected retro-orbital, and only MDS sample 8 (13% myeloblasts) had human cell engraftment in the bone marrow (0.16, 17.7% of engrafted cells were CD33 þ following injection of 2 Â 10 6 cells) (Figures 1a and  b) . To ensure that the viability of CD34 þ injected cells was not compromised during the purification process; we assessed their growth in normoxic methylcellulose culture (H4544, Stem Cell Technologies, Vancouver, BC, Canada). CD34 þ purified cells from the normal bone marrow and MDS sample 8 produced 52 and 14 CFU per 1,000 cells plated, respectively. Interphase
